Achillion Pharmaceuticals, Inc. (ACHN) EPS Estimated At $-0.13

August 9, 2018 - By Megan Stone

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) LogoInvestors sentiment decreased to 0.95 in Q1 2018. Its down 1.13, from 2.08 in 2017Q4. It is negative, as 26 investors sold Achillion Pharmaceuticals, Inc. shares while 29 reduced holdings. 17 funds opened positions while 35 raised stakes. 107.48 million shares or 2.61% less from 110.36 million shares in 2017Q4 were reported.
Cwm Lc invested in 0% or 75 shares. Acadian Asset Mngmt Ltd Com, Massachusetts-based fund reported 82,478 shares. Td Asset Mgmt holds 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 203,287 shares. 146,800 were reported by State Common Retirement Fund. National Bank Of Mellon Corp holds 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) or 626,669 shares. Tiaa Cref Mgmt Ltd Limited Liability Company reported 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Architects reported 1,200 shares. Jpmorgan Chase And Company owns 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 1.03 million shares. 163,700 were accumulated by California Employees Retirement System. Element Mngmt Limited Liability Company stated it has 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Jacobs Levy Equity Mgmt invested in 151,400 shares. Daiwa Secs Grp Incorporated Inc stated it has 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). 42,928 were reported by Principal Grp. Perceptive Advsr Ltd Liability has 0.1% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Secor Cap Ltd Partnership has invested 0.02% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Analysts expect Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to report $-0.13 EPS on August, 14.They anticipate $0.03 EPS change or 18.75 % from last quarter’s $-0.16 EPS. After having $-0.15 EPS previously, Achillion Pharmaceuticals, Inc.’s analysts see -13.33 % EPS growth. The stock increased 1.79% or $0.05 during the last trading session, reaching $2.56. About 375,306 shares traded. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 13.49% since August 9, 2017 and is downtrending. It has underperformed by 26.06% the S&P500.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Coverage

Among 2 analysts covering Achillion Pharmaceuticals (NASDAQ:ACHN), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Achillion Pharmaceuticals had 2 analyst reports since February 23, 2018 according to SRatingsIntel. The firm earned “Hold” rating on Friday, February 23 by FBR Capital. The firm has “Hold” rating given on Monday, May 21 by Barclays Capital.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. The company has market cap of $353.46 million. The Company’s drug candidates for treating chronic hepatitis C virus infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. It currently has negative earnings. The firm is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors.

More recent Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) news were published by: which released: “Benzinga’s Biotech Pulse: Pfizer’s Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke …” on August 01, 2018. Also published the news titled: “Achillion Is A Worthwhile Biotech Speculation” on July 12, 2018.‘s news article titled: “Achillion Reports Second Quarter 2018 Financial Results” with publication date: August 08, 2018 was also an interesting one.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.